Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.720 +0.050 (+1.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08. 
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview
 
Via Benzinga
C4 Therapeutics: Q3 Earnings Insights
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: C4 Therapeutics Q2 Earnings
  C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving. 
Via Benzinga
C4 Therapeutics: Q1 Earnings Insights
C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Where C4 Therapeutics Stands With Analysts
Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings: 
Via Benzinga
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million. 
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview
C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million. 
Via Benzinga
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial... 
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the... 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Why C4 Therapeutics Stock Is Plunging Today
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical... 
Via Benzinga
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.